Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital ...
A year after officially launching its AI agency offering, EVERSANA is expanding the platform’s capabilities and announcing a ...
Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care, ...
Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) for the ...
As clinical trials become more complex, sponsors face growing pressure to reach more representative patient populations while ...
The European Commission has granted marketing authorisation to Gilead for Trodelvy (sacituzumab govitecan-hziy) in ...
Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity ...
CHB is a major public health challenge and a leading cause of liver cancer globally. Chronic hepatitis B occurs when the ...
Eli Lilly has announced that orforglipron (Foundayo), its oral glucagon-like peptide-1 (GLP-1) receptor agonist, is now ...
Japanese pharma group Otsuka has signed an agreement to acquire Canada's Mindset Pharma, a specialist in psychedelic medicines for neuropsychiatric disorders. The all-cash deal – worth around C$80 ...
Acadia Pharmaceuticals has secured European Commission approval for DAYBU (trofinetide), opening the door to the first ...
Sanofi is laying off 229 former Blueprint Medicines employees in Cambridge, MA and closing two legacy Blueprint facilities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results